Discontinue treatment in the presence of dermatological bacterial or fungal infection until it has been adequately controlled; in the absence of clear etiology for lymphadenopathy or presence of acute infectious mononucleosis. Not recommended in patients w/ Netherton's syndrome or severely inflamed or damaged skin (eg, erythroderma); immunocompromised patients. Not to be applied to potentially malignant or pre-malignant skin lesions; areas affected by acute cutaneous viral infections. Malignancy eg, skin & lymphoma; lymphadenopathy. Avoid contact w/ eyes & mucous membranes; or minimize natural or artificial sunlight exposure throughout treatment. Re-examine patients if signs & symptoms persist beyond 6 wk. Resume treatment at 1st occurrence of signs & symptoms if discontinued. May cause mild & transient reactions at application site eg, feeling of warmth &/or burning sensation. Monitor patients who develop lymphadenopathy to ensure it resolves. Not recommended for application to vaccination sites. Pregnancy. Not to be applied on the breast of nursing mothers. Infants <3 mth.
Sign Out
